{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076058","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-06-22T11:00:29+00:00","discovered_at":"2026-06-22T11:05:01.252129+00:00","generated_at":"2026-06-22T11:05:45.381180+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Traws Pharma to resubmit TXM data package to UK MHRA in Q3 2026 for Phase 2a influenza challenge study","bullets":["Resubmission of updated toxicology data package to MHRA expected in Q3 2026.","Formal MHRA response anticipated within 30 days after resubmission.","Data package intended to enable Phase 2a human influenza Challenge study of tivoxavir marboxil (TXM).","TXM targets seasonal influenza prophylaxis; preclinical data showed broad in vitro efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076058","json":"https://secwatch.observer/filing/0001104659-26-076058.json","markdown":"https://secwatch.observer/filing/0001104659-26-076058.md","text":"https://secwatch.observer/filing/0001104659-26-076058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926076058/0001104659-26-076058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926076058/tm2618195d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:05:45.381180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}